896,700 Shares in Evommune, Inc. $EVMN Bought by Janus Henderson Group PLC

Janus Henderson Group PLC purchased a new position in Evommune, Inc. (NYSE:EVMN) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 896,700 shares of the company’s stock, valued at approximately $20,615,000.

Several other institutional investors have also added to or reduced their stakes in the business. Capricorn Fund Managers Ltd purchased a new position in shares of Evommune in the fourth quarter worth about $1,027,000. Sofinnova Investments Inc. purchased a new stake in Evommune during the 4th quarter valued at about $2,625,000. Seven Grand Managers LLC bought a new position in Evommune during the 4th quarter worth approximately $1,284,000. EQT Fund Management S.a r.l. purchased a new position in Evommune in the 4th quarter worth approximately $84,395,000. Finally, NEXTBio Capital Management LP bought a new stake in Evommune in the fourth quarter valued at approximately $3,908,000.

Evommune Stock Performance

NYSE EVMN opened at $11.65 on Tuesday. The stock has a market cap of $419.71 million and a P/E ratio of -1.23. Evommune, Inc. has a fifty-two week low of $10.47 and a fifty-two week high of $33.20. The stock has a 50 day simple moving average of $16.78 and a two-hundred day simple moving average of $21.34.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. Sell-side analysts predict that Evommune, Inc. will post -2.83 earnings per share for the current year.

Analyst Ratings Changes

EVMN has been the subject of a number of analyst reports. Wall Street Zen lowered Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Weiss Ratings lowered shares of Evommune from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Raymond James Financial cut shares of Evommune from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, June 29th. Oppenheimer initiated coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $48.00 price objective on shares of Evommune in a research report on Friday, April 10th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Evommune presently has an average rating of “Moderate Buy” and an average price target of $45.62.

Insiders Place Their Bets

In related news, Director Arthur S. Kirsch bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was purchased at an average cost of $13.30 per share, with a total value of $133,000.00. Following the transaction, the director owned 10,000 shares in the company, valued at approximately $133,000. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeegar Pravinkumar Patel sold 1,488 shares of Evommune stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $22.50, for a total transaction of $33,480.00. Following the sale, the insider directly owned 46,403 shares in the company, valued at $1,044,067.50. The trade was a 3.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 100,854 shares of company stock valued at $2,279,142 over the last quarter. 31.10% of the stock is owned by company insiders.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.